(Q53353394)

English

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

1 reference

Europe PubMed Central

Adding adjuvant CMF chemotherapy to either radiotherapy or tamoxifen: are all CMFs alike? The International Breast Cancer Study Group (IBCSG). (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

adaptive radiation therapy

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

A Goldhirsch

1

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

M Colleoni

2

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

A S Coates

3

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

M Castiglione-Gertsch

4

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

R D Gelber

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

publication date

1 May 1998

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

9

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

5

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

489-493

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Stopping metastases at their source

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination Chemotherapy as an Adjuvant Treatment in Operable Breast Cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investi

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant cyclophosphamide, methotrexate and fluorouracil in node-negative and estrogen receptor-negative breast cancer. Updated results

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of two regimens of cyclophosphamide, methotrexate, 5-fluorouracil, and prednisone in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

The International (Ludwig) Breast Cancer Study Group Trials I-IV: 15 years follow-up

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the Nationa

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of f

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant chemoendocrine therapy in postmenopausal breast cancer: cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference. International Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008236502420

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008236502420

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 May 2018

http://europepmc.org/abstract/MED/9653488

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53353394&oldid=1962218534"